Vor Biopharma (NYSE:VOR) Price Target Cut to $13.00 by Analysts at HC Wainwright

Vor Biopharma (NYSE:VOR) had its price target trimmed by HC Wainwright from $17.50 to $13.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also weighed in on the company. Stifel Nicolaus lowered their target price on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a report on Friday. Wedbush reaffirmed an “outperform” rating and set a $7.00 price objective on shares of Vor Biopharma in a research note on Thursday. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Tuesday, December 10th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $8.86.

Vor Biopharma Stock Performance

Vor Biopharma stock opened at $0.87 on Friday. The firm has a market capitalization of $59.75 million, a price-to-earnings ratio of -0.53 and a beta of -0.40. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $2.43. The stock’s fifty day moving average is $1.22 and its two-hundred day moving average is $1.01.

Hedge Funds Weigh In On Vor Biopharma

Large investors have recently added to or reduced their stakes in the business. Two Sigma Investments LP lifted its position in Vor Biopharma by 18.9% during the fourth quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock worth $181,000 after buying an additional 25,930 shares during the period. Northern Trust Corp lifted its position in Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock worth $175,000 after buying an additional 44,252 shares during the period. Trustees of Columbia University in the City of New York purchased a new position in Vor Biopharma during the fourth quarter worth about $102,000. RA Capital Management L.P. lifted its position in Vor Biopharma by 74.3% during the fourth quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock worth $44,007,000 after buying an additional 16,897,159 shares during the period. Finally, XTX Topco Ltd purchased a new position in Vor Biopharma during the fourth quarter worth about $80,000. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.